La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
China Resources Pharmaceutical Group Gestione
Gestione criteri di controllo 3/4
China Resources Pharmaceutical Group's Il CEO è Xiaosong Bai, nominato in Jan2022, e ha un mandato di 2.58 anni. la retribuzione annua totale è CN¥ 3.60M, composta da 98.6% di stipendio e 1.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.003% delle azioni della società, per un valore di HK$ 1.13M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.6 anni e 3.9 anni.
Informazioni chiave
Xiaosong Bai
Amministratore delegato
CN¥3.6m
Compenso totale
| Percentuale dello stipendio del CEO | 98.6% |
| Mandato del CEO | 2.6yrs |
| Proprietà del CEO | 0.003% |
| Durata media del management | 2.6yrs |
| Durata media del Consiglio di amministrazione | 3.9yrs |
Aggiornamenti recenti sulla gestione
Recent updates
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Jun 01
Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%
May 13China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon
Jan 28We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?
Aug 02With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case
May 26These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 04Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?
Jan 24Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 18China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15
May 29China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15
May 02China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's
Apr 07China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?
Feb 21Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Dec 07China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate
Nov 10These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
Aug 29Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?
Aug 03Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?
May 03Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?
Apr 12Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Mar 17An Intrinsic Calculation For China Resources Pharmaceutical Group Limited (HKG:3320) Suggests It's 24% Undervalued
Feb 14If You Had Bought China Resources Pharmaceutical Group's (HKG:3320) Shares Three Years Ago You Would Be Down 63%
Jan 17
We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Nov 29Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Dec 31 2023 | CN¥4m | CN¥4m | CN¥4b |
| Sep 30 2023 | n/a | n/a | CN¥4b |
| Jun 30 2023 | n/a | n/a | CN¥4b |
| Mar 31 2023 | n/a | n/a | CN¥4b |
| Dec 31 2022 | CN¥2m | CN¥2m | CN¥4b |
Compensazione vs Mercato: La retribuzione totale di Xiaosong ($USD 505.05K ) è circa la media per le aziende di dimensioni simili nel mercato Hong Kong ($USD 505.05K ).
Compensazione vs guadagni: La retribuzione di Xiaosong è aumentata di oltre il 20% nell'ultimo anno.
AMMINISTRATORE DELEGATO
Xiaosong Bai (53 yo)
2.6yrs
Mandato
CN¥3,601,000
Compensazione
Mr. Xiaosong Bai serves as Non-Independent Director of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. since March 3, 2022. He serves as Executive Director and Chief Executive Officer at China Re...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Executive Director | 2.6yrs | CN¥3.60m | 0.0032% CN¥ 1.1m | |
| VP & Executive Director | 2.9yrs | CN¥2.94m | Nessun dato | |
| CFO & Executive Director | 1.2yrs | Nessun dato | Nessun dato | |
| Chief Information Officer & VP | 10.7yrs | Nessun dato | Nessun dato | |
| Company Secretary | less than a year | Nessun dato | Nessun dato | |
| Vice President | no data | Nessun dato | Nessun dato | |
| Vice President of CR Pharma & Chairman of China Resources Boya | no data | Nessun dato | Nessun dato |
2.6yrs
Durata media
53yo
Età media
Gestione esperta: Il team dirigenziale di 3320 è considerato esperto (durata media dell'incarico 2.6 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Executive Director | 2.6yrs | CN¥3.60m | 0.0032% CN¥ 1.1m | |
| VP & Executive Director | 2.9yrs | CN¥2.94m | Nessun dato | |
| CFO & Executive Director | less than a year | Nessun dato | Nessun dato | |
| Independent Non-Executive Director | 8.2yrs | CN¥270.00k | Nessun dato | |
| Non-Executive Director | 2.6yrs | Nessun dato | Nessun dato | |
| Independent Non-Executive Director | 8.2yrs | CN¥270.00k | Nessun dato | |
| Independent Non-Executive Director | 8.2yrs | CN¥270.00k | Nessun dato | |
| Chairman of China Resources Double-Crane Pharmaceutical Co. | 5.7yrs | Nessun dato | Nessun dato | |
| Non-Executive Director | 1.5yrs | Nessun dato | Nessun dato | |
| Independent Non-Executive Director | 7yrs | CN¥270.00k | Nessun dato | |
| Chairman | 4.8yrs | Nessun dato | 0.0048% CN¥ 1.7m | |
| Non-Executive Director | less than a year | Nessun dato | Nessun dato |
3.9yrs
Durata media
57yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 3320 sono considerati esperti (durata media dell'incarico 3.9 anni).